UNICA IRIS Institutional Research Information System

CARTA, ANNAROSA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 134.991
NA - Nord America 5.600
AS - Asia 767
OC - Oceania 19
AF - Africa 17
SA - Sud America 10
Continente sconosciuto - Info sul continente non disponibili 5
Totale 141.409
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 133.517
US - Stati Uniti d'America 5.544
CN - Cina 606
UA - Ucraina 518
SE - Svezia 370
DE - Germania 179
GB - Regno Unito 138
FI - Finlandia 132
CA - Canada 51
FR - Francia 47
SG - Singapore 33
ES - Italia 25
IR - Iran 22
VN - Vietnam 21
IN - India 20
HK - Hong Kong 19
BE - Belgio 14
RU - Federazione Russa 14
AU - Australia 13
KR - Corea 12
NL - Olanda 9
EG - Egitto 8
BR - Brasile 7
IE - Irlanda 7
IL - Israele 7
JP - Giappone 6
NZ - Nuova Zelanda 6
EU - Europa 5
ID - Indonesia 5
MX - Messico 5
HR - Croazia 4
MU - Mauritius 4
SA - Arabia Saudita 4
TR - Turchia 4
CL - Cile 3
PL - Polonia 3
CZ - Repubblica Ceca 2
LU - Lussemburgo 2
PH - Filippine 2
PK - Pakistan 2
PT - Portogallo 2
TN - Tunisia 2
ZA - Sudafrica 2
AT - Austria 1
CH - Svizzera 1
EE - Estonia 1
HU - Ungheria 1
JO - Giordania 1
KE - Kenya 1
LT - Lituania 1
MM - Myanmar 1
MY - Malesia 1
RO - Romania 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 141.409
Salva come PNG Salva come JPEG
Città #
Cagliari 133.109
Fairfield 815
Woodbridge 588
Chandler 496
Houston 392
Seattle 346
Wilmington 339
Ashburn 333
Ann Arbor 327
Nyköping 291
Jacksonville 278
Cambridge 265
Dearborn 207
Beijing 116
Boardman 111
Nanjing 99
Hangzhou 89
Boston 69
Shanghai 69
San Diego 59
Helsinki 56
New York 48
Nanchang 30
Toronto 29
Redwood City 28
Shenyang 26
Milan 25
Changsha 24
Norwalk 23
Mountain View 22
Dong Ket 20
Hebei 20
Guangzhou 19
Sassari 17
Jinan 16
London 16
Verona 16
Assèmini 15
Barcelona 15
Brussels 14
Jiaxing 14
San Mateo 14
Atlanta 13
Tianjin 13
Hefei 12
Los Angeles 12
Orange 11
Zhengzhou 10
Auburn Hills 9
Augusta 9
Torino 9
Washington 9
Kilburn 8
Indiana 7
Rome 7
Central 6
Cosenza 6
Ningbo 6
Pune 6
Sherbrooke 6
Chicago 5
Dublin 5
Phoenix 5
Sezze 5
Taizhou 5
Capoterra 4
Catania 4
Falls Church 4
Kunming 4
Millbury 4
Murcia 4
Palo Alto 4
Saint Petersburg 4
Tehran 4
Tel Aviv 4
Zagreb 4
Aughton 3
Baveno 3
Bethesda 3
Bloomington 3
Brampton 3
Brisbane 3
Brooklyn 3
Detroit 3
Durham 3
Florence 3
Geislingen an der Steige 3
Hangyang 3
Huntington Beach 3
Indianapolis 3
Lemont 3
Lissone 3
Lodz 3
Monmouth Junction 3
Montreal 3
Morcone 3
Mumbai 3
Pownal 3
Sinnai 3
Siracusa 3
Totale 139.205
Salva come PNG Salva come JPEG
Nome #
Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease 4.986
Nematicidal activity of 2-thiophenecarboxaldehyde and methylisothiocyanate from caper (Capparis spinosa) against Meloidogyne incognita 4.191
null 4.110
Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice 3.416
Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson's disease 3.350
The MPTP/probenecid model of progressive Parkinson's disease 3.038
Role of Adenosine in the basal Ganglia 2.998
Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. 2.951
PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests nigrostriatal degeneration in a progressive Parkinson’s disease model. 2.881
A442 PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests neurodegeneration in a progressive Parkinson´s disease model 2.695
Microglial phenotypes in Parkinson's disease and animal models of the disease 2.669
Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease 2.650
null 2.592
Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? 2.584
Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function 2.555
L dopa chronic treatment increases reactive microglia and tnf- alpha production in the 6-ohda lesioned striatum 2.435
L-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role? 2.408
Modulating microglia activity with PPAR-gamma agonists: a promising therapy for Parkinson's disease? 2.368
Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson’s disease 2.304
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats 2.239
Disease modifying treatment with PPAR-gamma agonist rosiglitazone in a progressive mouse model of Parkinson's disease 2.144
Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson's Disease 2.137
Trimethyl chitosan hydrogel nanoparticles for progesterone delivery in neurodegenerative disorders 2.119
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease 1.954
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 1.871
null 1.857
SELECTIVE CHANGES IN DENDRITIC SPINES OF STRIATAL MEDIUM SPINY NEURONS IN A CHRONIC MOUSE MODEL OF PARKINSON'S DISEASE. 1.815
The role of microglia–lymphocyte interaction in PD neuropathology 1.768
Nicotine, cocaine, amphetamine, morphine, and ethanol increase norepinephrine output in the bed nucleus of stria terminalis of freely moving rats 1.765
PPAR-GAMMA RECEPTOR AGONIST PREVENTS NEURODEGENERATION AND BEHAVIOURAL DEFICITS IN A CHRONIC MPTP MOUSE MODEL OF PARKINSON’S DISEASE. 1.746
PPAR-γ: Therapeutic Prospects in Parkinson's Disease. 1.707
The interrelationship between dopamine and noradrenaline in the prefrontal cortex: From physiology to therapy 1.697
Dyskinesia in Parkinson's disease therapy 1.664
null 1.651
PROGRESSIVE DECLINE OF BEHAVIORAL AND BIOCHEMICAL PARAMETERS IN THE CHRONIC MPTP/PROBENECID MOUSE MODEL OF PARKINSON’S DISEASE. 1.627
Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson’s Disease 1.626
Farmaci antiparkinsoniani ed attivi in altri disturbi motori 1.585
PEROXIZOME-PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARG) AGONIST ROSIGLITAZONE COUNTERACTS BEHAVIORAL AND BIOCHEMICAL DEFICITS IN A CHRONIC 1-METHYL-4-PHENIL-1,2,3,4 TETRAHYDROPYRIDINE (MPTP) MOUSE MODEL OF PARKINSON’S DISEASE 1.574
Microglial phagocytosis and its regulation: A therapeutic target in parkinson’s disease? 1.429
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1.408
Farmaci utilizzati nella terapia della Malattia di Parkinson e di altri disturbi motori 1.353
Advances in modelling alpha-synuclein-induced Parkinson's diseases in rodents: virus-based models versus inoculation of exogenous preformed toxic species 1.343
Controversie: Priming dopaminergico nel Parkinson. Il "priming" come modello sperimentale delle discinesie indotte da terapie dopaminergiche sostitutive nella Malattia di Parkinson 1.299
Beneficial effects of curtailing immune susceptibility in an Alzheimer's disease model 1.243
null 1.194
Long-term increase in GAD67 mRNA expression in the central amygdala of rats sensitized by drugs and stress 1.170
null 1.108
Adenosine signaling in the basal ganglia 1.093
Caffeine sensitization and cross-sensitization with amphetamine: association to post-synaptic changes in rat striatal neurons 1.057
Can pioglitazone be potentially useful therapeutically in treating patients with Covid-19? 1.037
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence 1.019
null 1.012
The 6-hydroxydopamine model of Parkinson's disease 1.001
null 981
Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease 978
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats 935
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease 910
CAFFEINE SESITIZATION AND CROSS-SENSITIZATION WITH AMPHETAMINE: ASSOCIATION TO POST-SYNAPTIC CHANGES IN RAT STRIATAL NEURONS 910
Dopamine and adenosine receptor interaction as the basis for the treatment of Parkinson's disease 901
Adenosine A2A receptors and Parkinson's disease 892
The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications 891
CAFFEINE SENSITIZATION AND CROSS-SENSITIZATION WITH AMPHETAMINE: ASSOCIATION TO POST BUT NOT PRE-SYNAPTIC CHANGES IN RAT STRIATAL NEURON 873
null 830
Metabolomics fingerprint induced by the intranigral inoculation of exogenous human alpha-synuclein oligomers in a rat model of Parkinson’s disease 828
Modeling Parkinson’s disease neuropathology and symptoms by intranigral inoculation of preformed human α-synuclein oligomers 810
null 801
Changes in the expression of tonic and phasic neurochemical markers of activity in a rat model of L-DOPA induced dyskinesia 781
Changes in the expression of tonic and phasic neurochemical markers of activity in a rat model of L-DOPA induced dynskinesia 779
Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats 767
How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease? 717
Differential effect of MK 801 and scopolamine on c-fos expression induced by L-dopa in the striatum of 6-hydroxydopamine lesioned rats 715
Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment 710
Blockade of muscarinic receptors potentiates D1 dependent turning behavior and c-fos expression in 6-hydroxydopamine-lesioned rats but does not influence D2 mediated responses 634
Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson’s disease 629
Effect of MK 801 on priming of D-1-dependent contralateral turning and its relationship to c-fos expression in the rat caudate-putamen 620
Modulation of dopamine d1-mediated turning behavior and striatal c-fos expression by the substantia nigra 612
“Priming” to dopamine agonist-induced contralateral turning as model of non associative sensitization to the expression of the post-synaptic dopamine message 591
Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease 588
Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation 563
Cocaine effects on gene regulation in the striatum and behavior: increased sensitivity in D3 dopamine receptor-deficient mice 555
null 515
Changes in GAD67 and peptides mRNA levels in specific populations of striatal efferent neurons following priming with dopamine agonists in 6-OHDA lesioned rats 511
GABA(A) receptors mediate orexin-A induced stimulation of food intake. 510
Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats 483
Alterazioni nei livelli striatali di RNAm della GAD67, dinorfina e enkefalina, in seguito a priming con agonisti dopaminergici nel modello di morbo di parkinson della 6-ohda 475
Different patterns of behavior and gene expression induced by chronic L-DOPA and A2A antagonists plus L-DOPA treatments in 6-hydroxydopamine lesioned rats 473
Differential effect of priming with dopamine agonists on mrna for GAD-67, dynorphin and enkephalin in 6-OHDA lesioned rats 471
Lack of a role for the D3 receptor in clozapine induction of c-fos demonstrated in D3 dopamine receptor-deficient mice 470
Expression offunctional leptin receptors in rodent leydig cells 445
Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders 444
Blockade of A2A receptors plus L-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from L-DOPA alone in the rat globus pallidus and substantia nigra reticulata 430
null 425
Farmaci antiparkinsoniani ed attivi in altri disturbi motori 405
Modulation of turning behavior induced by dopamine D1 agonists in 6-hydroxydopamine lesioned rats by intranigral infusion of glutamate antagonists. 388
Role of prefrontal cortex dopamine and noradrenaline circuitry in addiction 387
MPTP: Advances from an Evergreen Neurotoxin 376
Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous L-DOPA delivery in the 6-OHDA model of Parkinson's disease 371
EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease 361
Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success? 349
BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression 346
Totale 138.929
Salva come PNG Salva come JPEG
Categoria #
all - tutte 166.099
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 166.099
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.151 0 0 0 0 0 0 0 0 0 0 716 435
2019/202027.450 1.279 988 212 465 9.667 6.455 3.814 926 800 957 776 1.111
2020/202138.614 1.555 1.609 2.144 9.674 7.371 4.380 3.302 2.350 1.186 1.926 1.735 1.382
2021/20228.062 1.090 465 470 646 618 417 493 409 759 912 869 914
2022/202314.219 1.057 1.774 1.717 1.115 966 1.524 863 1.000 1.004 1.130 1.452 617
2023/202411.198 605 638 656 772 1.377 2.227 2.265 999 562 976 121 0
Totale 141.703